Summary
Sandoz aims to more than double its annual net sales by 2035, with biosimilars driving this growth, and plans to expand its biosimilar portfolio to 100 drugs by 2040. The company will invest an additional $300 million in a Slovenian manufacturing facility to support its mid-to-high single-digit sales growth target.